High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients

Efficacy and safety of brentuximab vedotin plus bendamustine in advanced‐stage primary cutaneous T‐cell lymphomas

“…Bendamustine has been previously associated with renal toxicity in patients treated with higher doses for autologous stem‐cell transplantation; age > 60 years was a risk factor . Both patients with acute renal failure in our study were older than 60 years.…”

Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers

“…16,17,26,27 Identifying factors that indicate patients at risk of ARF such as age over 55 years, a history of previous ARF and the use of concomitant nephrotoxic drugs could stratify patients for ARF risk and adapt supportive care strategy. 20,28 Furthermore, 47% of patients presented with grade III-IV mucositis, which is more frequent than in previous studies on the BEAM regimen. 29,30,31,18 Gastro intestinal toxicity could explain the high rate of septicemia with bacteria from digestive tract but as renal toxicity, it remained manageable and was not associated with increased NRM in our study.…”

Prophylactic corticosteroid use prevents engraftment syndrome in patients after autologous stem cell transplantation

“…In the lymphoma patients, CD34 + mobilization was consistently performed following mobilization with vinorelbine and G‐CSF 28 . High‐dose chemotherapy was melphalan‐based in the myeloma patients (100 mg/m 2 /day on days 2 and 1; cumulative dose/m 2 ), combined with bendamustine 6,29,30 . Lymphoma patients received the BeEAM (Bendamustine, etoposide, cytarabine, and melphalan) regimen 8 .…”

“…Since more than 3 decades, autologous stem cell transplantation (ASCT) is a key component of standard therapy for patients with multiple myeloma, relapsing lymphomas, acute myeloid leukemia (AML), and relapsing testicular or germ cell neoplasms 1–6 . Although transplant‐related mortality (TRM) associated with ASCT can be as low as 1%–2%, 7,8 ASCT may be associated with relevant side effects.…”